Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec 19;2013(12):CD009546.
doi: 10.1002/14651858.CD009546.pub2.

Anticholinergic medication for non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia

Adib Essali  1 , Anas Rihawi, Mohammad Altujjar, Bishr Alhafez, Amjad Tarboush, Nahla Alhaj Hasan
Affiliations

Anticholinergic medication for non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia

Adib Essali et al. Cochrane Database Syst Rev. .

Abstract

Background: Treatment of schizophrenia depends heavily on neuroleptic drugs. Hypersalivation is a common side effect when people with schizophrenia are treated with neuroleptic drugs. Hypersalivation can be an embarrassing and stigmatising problem, can affect quality of life and can result in discontinuation of neuroleptic treatment. It can also be difficult to treat.

Objectives: To summarise the best available evidence of the effects of anticholinergic drugs in the treatment of non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia. Clozapine-induced hypersalivation has been addressed in another Cochrane review.

Search methods: We searched the Cochrane Schizophrenia Group Trials Register (15 November 2012) and inspected references of all identified studies for further relevant studies. We were to contact the first author of each included study for information regarding unpublished trials.

Selection criteria: All randomised controlled trials comparing an anticholinergic drug with placebo, no treatment, another anticholinergic drug or any other intervention.

Data collection and analysis: We inspected the results of the search to identify relevant studies. We were to extract data onto standard, simple forms. Disagreements were resolved through discussion. The risk of bias was to be assessed using the Cochrane risk assessment tool. For binary outcomes, we were to calculate a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). For continuous outcomes, we were to estimate the mean difference between groups.

Main results: The search resulted in four potential studies; after inspection, all were excluded. Three studies were excluded because they involved people with clozapine-induced hypersalivation - a topic covered in another Cochrane review. The fourth study was excluded because it involved people with schizophrenia, mood disorders or other mental disorders who were suffering from clozapine- and non-clozapine induced hypersalivation and were treated with Chinese medicines with unknown anticholinergic properties. People in the control group received an anticholinergic drug (artane) or an antihistamine (phenergan). It was not possible to separate clozapine- from non-clozapine-treated people in the intervention group, or to separate artane-treated people from phenergan-treated people in the control group.

Authors' conclusions: We have been unable to locate any studies addressing the question raised in this review. Accordingly, this empty review points out an important clinical problem that needs to be investigated via well-designed and well-conducted randomised trials. Clinicians and patients are likely to continue with their current dependence on clinical judgement and personal experience. Policy makers have no trial-based evidence upon which to base guidelines for the treatment of hypersalivation induced by neuroleptics other than clozapine. They are likely to continue to rely on opinion and habit when making recommendations. Funders of studies may wish to make this important subgroup of people a priority in future research.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

1
1
Study flow diagram.
See this image and copyright information in PMC

Update of

References

References to studies excluded from this review

Bai 2001 {published data only}
    1. Bai YM, Lin CC, Chen JY, Liu WC. Therapeutic effect of pirenzepine for clozapine‐induced hypersalivation: a randomized, double‐blind, placebo‐controlled, cross‐over study. Journal of Clinical Psychopharmacology 2001;21(6):608‐11. [MEDLINE: ] - PubMed
Hui 2002 {published data only (unpublished sought but not used)}
    1. Flaws B. The Chinese medical treatment of hypersalivation as an adverse reaction to anti‐pyschotic medication. Blue Poppy Press 2003. [http://bluepoppy.com/cfwebstore/index.cfm/feature/898/the‐chinese‐medica...
    1. Hui L, Xingxing P. Treatment of neuroleptic salivation by Chinese Luijunazi Wan: a clinical observation of 56 cases. China Academic Journal 2002;8:19‐29.
ISRCTN47146067 2010 {published data only}
    1. ISRCTN47146067. Reducing excess salivation in clozapine treatment: hyoscine for the treatment of clozapine induced nocturnal sialorrhoea, 2010. http://www.controlled‐trials.com.
Reinstein 1999 {published data only}
    1. Reinstein MJ, Sirotovskaya LA, Chasanov MA, Jones LE, Mohan S. Comparative efficacy and tolerability of benzatropine and terazosin in the treatment of hypersalivation secondary to clozapine. Clinical Drug Investigation 1999;17(2):97‐102.

Additional references

Almeida‐Filho 1997
    1. Almeida‐Filho N, Mari JJ, Coutinho ESF, França J, Fernandes J, Andreoli SB, et al. Brazilian multicentric study of psychiatry morbidity: methodological features and prevalence estimates [Estudo multicêntrico de morbidade psiquiátrica em áreas urbanas brasileiras (Brasilia, São Paulo, Porto Alegre)]. British Journal of Psychiatry 1997;171:524‐9. - PubMed
Altman 1996
    1. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200. - PMC - PubMed
Antonello 1999
    1. Antonello C. Clozapine and sialorrhea: a new intervention for this bothersome and potentially dangerous side effect. Journal of Psychiatry and Neuroscience 1999;24:250. - PMC - PubMed
Bland 1997
    1. Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600. - PMC - PubMed
Boissel 1999
    1. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'etude des Indices d'efficacite]. Therapie 1999;54(4):405‐11. [PUBMED: 10667106] - PubMed
Calderon 2000
    1. Calderon J, Robin E, Sobota WL. Potential use of ipatropium bromide for the treatment of clozapine‐induced hypersalivation: a preliminary report. International Clinical Psychopharmacology 2000;15:49‐52. - PubMed
Carpenter 1994
    1. Carpenter WT Jr, Buchanam RW. Schizophrenia. New England Journal of Medicine 1994;330:681‐90. - PubMed
Corrigan 1995
    1. Corrigan F, MacDonald S, Reynolds G. Clozapine‐induced hypersalivation and the alpha2 adrenoceptor. British Journal of Psychiatry 1995;167:412. - PubMed
Deeks 2000
    1. Deeks J. Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
Divine 1992
    1. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623‐9. - PubMed
Donner 2002
    1. Donner A, Klar N. Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine 2002;21(19):2971‐80. - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34. - PMC - PubMed
Elbourne 2002
    1. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9. - PubMed
Fritz 1995
    1. Fritz J, Tilmann E. Pirenzepine for clozapine‐induced hypersalivation. Lancet 1995;346:1034. - PubMed
Furukawa 2006
    1. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7‐10. - PubMed
Gulliford 1999
    1. Gulliford MC. Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149(9):876‐83. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.2 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org.
Hori 2006
    1. Hori T, Makabe K, Nemoto K, Asada T. Hypersalivation induced by olanzapine with fluvoxamine. Progress in Neuro‐Psychopharmacology and Biological Psychiatry 2006;30(4):758‐60. - PubMed
Kay 1986
    1. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986.
Leucht 2005
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2‐3):231‐8. [PUBMED: 15982856] - PubMed
Leucht 2005a
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry 2005;187:366‐71. [PUBMED: 16199797] - PubMed
Leucht 2007
    1. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183‐91. [PUBMED: 16905632] - PMC - PubMed
Mandel 1975
    1. Mandel J, Zengo A, Katz R, Wotman S. Effects of adrenergic agents on salivary composition. Journal of Dental Research 1975;54:B27‐B33. - PubMed
Marshall 2000
    1. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249‐52. - PubMed
Miyamoto 2005
    1. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry 2005;10:79‐104. - PubMed
Overall 1962
    1. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799‐812.
Ozbilen 2009
    1. Ozbilen M, Adams CE. Systematic overview of Cochrane reviews for anticholinergic effects of antipsychotic drugs. Journal of Clinical Psychopharmacology 2009;29(2):141‐6. - PubMed
Safferman 1991
    1. Safferman A, Liberman J, Kane M, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophrenia Bulletin 1991;17:247‐61. - PubMed
Schünemann 2008
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359‐83.
Spivak 1997
    1. Spivak B, Adlersberg S, Rosen L, Gonen N, Mester R, Weizman A. Trihexyphenidyl treatment of clozapine induced hypersalivation. International Clinical Psychopharmacology 1997;12:213‐15. - PubMed
Syed 2008
    1. Syed R, Au K, Cahill C, Duggan L, He Y, Udu V, et al. Pharmacological interventions for clozapine‐induced hypersalivation. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD005579.pub2] - DOI - PMC - PubMed
Ukai 1989
    1. Ukai Y, Taniguchi T, Kimura K. Muscarinic supersensitivity and subsensitivity induced by chronic treatment with atropine and disopylfluorophosphate in rat submaxillary glands. Archives of International Pharmacodynamic Therapy 1989;6:148‐57. - PubMed
Ukoumunne 1999
    1. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PG. Methods for evaluating area‐wide and organisation‐based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii‐92. - PubMed
Xia 2009
    1. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El‐Sayeh H. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254‐7.
Yaffe 2012
    1. Yaffe J, Montgomery P, Hopewell S, Shepard LD. Empty reviews: a description and consideration of Cochrane systematic reviews with no included studies. PLoS ONE 2012;7(5):e36626. [DOI: 10.1371/journal.pone.0036626] - DOI - PMC - PubMed
Zorn 1994
    1. Zorn S, Jones S, Ward K, Liston D. Clozapine is a potent and selective muscarinic M4 receptor agonist. European Journal of Pharmacology 1994;269:R1‐2. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources